

Recurrent Fever Syndromes in Patients After Recovery From Kawasaki Syndrome

AUTHORS: Lori Broderick, MD, PhD,^a Adriana H. Tremoulet, MD,^a Jane C. Burns, MD,^a John F. Bastian, MD,^{a,b} and Hal M. Hoffman, MD^{a,b,c}

^aDepartment of Pediatrics, University of California San Diego and Rady Children's Hospital, San Diego, California; ^bDivision of Allergy and Immunology, University of California San Diego and Rady Children's Hospital, La Jolla, California; and ^cSan Diego Branch, Ludwig Institute of Cancer Research, La Jolla, California

KEY WORDS

recurrent fever, Kawasaki syndrome, autoinflammatory syndromes

ABBREVIATIONS

KS—Kawasaki syndrome

IVIg—intravenous immunoglobulin

PFAPA—periodic fever, aphthous stomatitis, pharyngitis and adenitis

www.pediatrics.org/cgi/doi/10.1542/peds.2010-1218

doi:10.1542/peds.2010-1218

Accepted for publication Oct 22, 2010

Address correspondence to Lori Broderick, MD, PhD, 9500 Gilman Dr, MC 0635, La Jolla, CA 92093. E-mail: lbroderick@ucsd.edu

PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275).

Copyright © 2011 by the American Academy of Pediatrics

FINANCIAL DISCLOSURE: *The authors have indicated they have no financial relationships relevant to this article to disclose.*

Funded by the National Institutes of Health (NIH).

abstract



The recurrence of fever in a child with a history of Kawasaki syndrome (KS) poses a dilemma for clinicians who must consider the possibility of recurrent KS. In this report we present the cases of 4 patients who presented with classical symptoms of KS, were successfully treated with intravenous immunoglobulin, and later experienced a reappearance of inflammatory symptoms in a pattern consistent with a recurrent fever syndrome. The association of these syndromes within the same patient suggests that some patients may have a genetic propensity toward altered immune responses and autoinflammatory syndromes. We propose that these 2 syndromes exist within a family of febrile disorders related to innate immune dysregulation. *Pediatrics* 2011;127:e489–e493

The diagnosis of Kawasaki syndrome (KS) is based on clinical criteria with no specific laboratory diagnostic test.¹ Early treatment with intravenous immunoglobulin (IVIg) is important for reducing the risk of cardiac sequelae.² With increasing awareness of KS cases with incomplete clinical signs, or IVIg resistance with persistent fever after treatment,^{3,4} the distinction between recurrent KS and other fevers of unknown origin, specifically the recurrent fever syndromes, becomes more difficult.

The term “recurrent fever syndrome” encompasses a number of genetically defined autoinflammatory disorders as well as clinically defined entities such as periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome. The hereditary fever disorders consist of recurrent episodes of fever associated with specific constellations of rash, lymphadenopathy, oral ulcerations, ocular findings, abdominal complaints, and arthralgias,⁵ whereas patients with PFAPA syndrome have fever episodes at regular intervals with associated symptoms often limited to the head and neck. Many patients with hereditary fever disorders have evidence of chronic inflammation, whereas patients with PFAPA syndrome are completely healthy between episodes and demonstrate normal growth and development.

The presence of these 2 conditions within a single patient suggests a possible genetic predilection for inflammatory dysregulation. Indeed, recent reports have implicated mutations in immunoregulatory pathways in the pathogenesis of KS.⁶ Such defects may also result in an increased likelihood of developing other inflammatory syndromes such as the recurrent fever disorders. In this report, we highlight 1 representative case among 4 patients who were initially diagnosed with KS

TABLE 1 Signs and Symptoms Present at Time of KS Diagnosis

Signs and Symptoms	Patient 1	Patient 2	Patient 3	Patient 4
Age at diagnosis, mo	36	14	12	10
Gender	Male	Female	Male	Male
Ethnicity	White	Hispanic	White	Hispanic
Duration of fever, d	7	35	10	7
Pharyngitis	—	+	+	+
Lymphadenopathy	+	+	+	+
Conjunctival injection	+	+	+	+
Strawberry tongue	+	+	—	+
Exanthem	+	+	+	+
Edema/peeling	—	+	—	+
C-reactive protein, mg/dL	NA	7.4	NA	3.8
Erythrocyte sedimentation rate, mm/h	94	6	NA	49
Urinalysis	NA	Negative	NA	Sterile pyuria
Echocardiogram	Normal	Coronary artery dilatation	Normal	Normal

NA indicates not applicable.

and successfully treated with IVIg and who subsequently developed recurrent fever syndromes.

CASE REPORTS

A 3-year-old white boy presented with a 7-day history of fever to 105°F, rash, injected conjunctivae, swollen lips, strawberry tongue, and edema of the hands and feet. Laboratory investigation revealed marked inflammation with an erythrocyte sedimentation rate of 94 mm/hour. He was diagnosed with KS on the seventh day of fever, successfully treated with 1 dose of IVIg (2 g/kg), and initiated on aspirin therapy. An echocardiogram showed no cardiovascular abnormalities (Table 1). Two years after his initial diagnosis of KS, he developed recurrent episodes of fever associated with oral ulcers, pharyngitis, lymphadenopathy, headache, nausea, and vomiting. These febrile episodes occurred every 3 weeks and lasted 4 to 5 days. The maximum temperatures reached during these episodes ranged from 102°F to 105°F. Results of multiple streptococcal throat cultures were negative. Febrile episodes were successfully terminated with prednisolone (1 mg/kg) administered at the onset of fever, but recurrent use of steroids shortened the periodicity of the fever cycle to 2-week intervals and thereafter were

limited to only intermittent use. Between febrile episodes, he was well with normal growth and development and no recurrent infectious illnesses. By the age of 11, the patient’s febrile episodes spontaneously resolved without apparent sequelae.

We have observed this pattern in 3 additional patients to date (summarized in Table 1). Each of these patients presented at younger than 5 years and met the classical criteria for KS. Each was treated successfully with 2 g/kg IVIg for the initial presentation of KS but developed recurrent fevers in the months after resolution of KS symptoms. Despite the variation in time to develop a recurrence of fevers, each of the patients developed a defined pattern of symptoms that fit a recurrent fever syndrome (Table 2). In 2 of the 3 cases, fevers were similarly responsive to prednisolone, and recurrent episodes resolved after tonsillectomy in the other case.

DISCUSSION

We report a series of 4 patients who each met clinical criteria for KS and had an appropriate response to standard IVIg therapy but subsequently developed recurrent febrile episodes within weeks to months after the initial KS diagnosis. We propose that this as-

TABLE 2 Summary of Recurrent Febrile Episodes in 4 Patients With a History of KS

	Patient 1	Patient 2	Patient 3	Patient 4
Time to fever recurrence, mo	24	12	5	2
Duration of episodes, d	4 to 5	4 to 5	4	1 to 10
Periodicity of fevers, wk	3	4	6	2
Pharyngitis	+	—	+	+
Aphthous stomatitis	+	+/-	—	+
Lymphadenitis	+	+	+	+
Eye symptoms	—	+	—	+
Abdominal pain	+	—	—	—
Nausea/vomiting	+	—	—	—
Myalgias/arthritis	—	—	—	—
Rash	+	—	—	+
C-reactive protein, mg/dL	<0.3	<0.5 to 7.4	NA	<0.3 to 8.5
Erythrocyte sedimentation rate, mm/h	3 to 94	1 to 6	NA	10 to 82
Prednisone responsive?	Yes	Yes	Not used	Yes
Final diagnosis	PFAPA	PFAPA	PFAPA	Atypical PFAPA
Time to resolution, y	6	— ^a	1.5 ^b	4

NA indicates not applicable.

^a Lost to follow-up.

^b Tonsillectomy.

sociation may be attributable to shared genetic links influenced by environmental factors, and we encourage primary care pediatricians to consider recurrent fever syndromes in the differential diagnosis of patients with a history of KS.

Recurrence of prolonged fevers in a patient with a history of KS presented a clinical challenge of distinguishing between recurrent KS versus a recurrent fever syndrome. Recurrent KS occurs in up to 10% of Japanese children with a history of KS and an unknown, although much lower, percentage of children of other genetic backgrounds.⁷⁻⁹ Further complicating the differential diagnosis is the frequent occurrence of incomplete KS in infants and younger children.^{7,10} Pattern recognition of symptoms subsequently led to the diagnosis of a recurrent fever syndrome. The differential diagnosis of recurrent fevers included the hereditary recurrent fever syndromes as well as PFAPA syndrome. In 3 of 4 cases, the febrile episodes were responsive to single, low-dose prednisone, which is consistent with a diagnosis of PFAPA syndrome. For patient 4, the symptomatology and prednisone responsiveness were consistent with

PFAPA syndrome, although the length of the febrile episodes was atypical. In each case, the patients were well between episodes and had normalized C-reactive protein levels. The clinical presentations, lack of chronic inflammation, ethnicity, and the ultimate disappearance of recurrent fever episodes made a hereditary fever syndrome unlikely. Although genetic testing is available for the known hereditary fever syndromes, it was not performed for these patients. As the pathogenesis of PFAPA syndrome is currently unknown, no specific gene test is available, and the mechanism behind the development of recurrent fevers in these patients remains an enigma.

We have identified a population of pediatric patients in San Diego, California, with recurrent fever syndromes (unpublished data), and systematic review of our patients' histories revealed the cases discussed above and also 4 additional patients with recurrent fever syndrome with first-degree relatives with a history of KS. At this time, it is unclear whether the association between KS and PFAPA syndrome in these patients represents a genetic predisposition to autoinflammatory responses, susceptibility to environmen-

tal exposures, or a combination of the two. The low prevalence of these 2 syndromes poses a challenge to answering this question.

The general prevalence of recurrent fever disorders, other than the hereditary syndromes reported in specific geographic regions, is not well established.¹¹ Over the last 3 years, we have identified 84 cases of recurrent fever syndromes of various etiologies in children in San Diego County (unpublished data), which yields an annual incidence of 9 to 34 in 100 000 children younger than 18 years, whereas the annual incidence of KS in San Diego County is 21.7 in 100 000 children younger than 5 years.¹² We estimate that the probability of a child having both of these rare conditions to be $<5 \times 10^{-6}$ or 1 in 19 million, on the basis of available data from San Diego County. Thus, 4 cases of KS among 84 patients with known recurrent fever syndrome (4.7%) is higher than would be expected by chance alone.

The association of KS and other immune-mediated conditions has been recognized, as has been recognized between KS and atopy^{13,14} and KS and psoriasis in children,¹⁵ which suggests that patients with KS may have a general propensity toward immunodysregulation. The similarities between the presentation of KS and recurrent fever syndromes may suggest activation of similar pathways that trigger innate immune responses. In addition, similarities in cytokine profiles are apparent in acute KS and in recurrent fever syndromes, including elevations in the levels of tumor necrosis factor α (TNF- α), interleukin 1 β (IL-1 β), and IL-6, and several recent studies found that IVIg increases the level of IL-1Ra,^{16,17} an inhibitor of the cytokine IL-1 β that has been shown to be important in the pathogenesis of several autoinflammatory syndromes.^{18,19} As such, we hypothesize that KS and

TABLE 3 Features of KS and Recurrent Fever Syndrome^{5,20,21}

Syndrome	Duration	Positive Diagnostic Criteria	Standard/Reported Treatments	Genetics
Classical Kawasaki syndrome	Single episode or recurrent, >5 d	Four of the following symptoms: bilateral conjunctival injection, oral mucosal changes, polymorphous rash, erythema/edema of palms/soles or desquamation of fingertips/toes, cervical adenopathy	IVIg infusion, TNF inhibitors ^a	No known genetic mutation
PFAPA syndrome	Recurrent, 3–5 d, regular intervals	Aphthous stomatitis, pharyngitis, cervical lymphadenitis; exclusion of bacterial infection/cyclic neutropenia	Corticosteroids, colchicine, tonsillectomy ^a	No known genetic mutation
Hyperimmunoglobulin D syndrome (HIDS) with periodic fever	Recurrent, 3–7 d	Fever, abdominal pain, oral ulcers, arthralgia, vomiting, diarrhea	Anakinra ^a	Autosomal recessive defect in <i>MVK</i> affecting mevalonic kinase
TNF receptor-associated periodic syndrome (TRAPS)	Recurrent, >1 wk	Fever, abdominal pain, centrifugal rash, periorbital edema, migratory arthralgia	Corticosteroids, anakinra, etanercept	Autosomal dominant defect in <i>TNFRSF1A</i> gene affecting TNFR
Familial Mediterranean fever (FMF)	Recurrent, 2 d	Sterile peritonitis with abdominal pain, monoarthritis, myalgia, erysipelas-like erythema (shins/foot)	Colchicine, Anakinra ^a	Autosomal recessive defect in <i>MEFV</i> , affecting pyrin
Familial cold autoinflammatory syndrome (FCAS)	Recurrent, <1 d	Arthralgia, cold-induced urticarial-like rash, conjunctivitis	Anakinra, rilonacept, canakinumab	Autosomal dominant defect in <i>NLRP3</i> , affecting cryopyrin
Muckle-Wells syndrome (MWS)	Recurrent, 1–2 d	Arthralgia, generalized urticarial-like rash, conjunctivitis, sensorineural hearing loss	Anakinra, rilonacept, canakinumab	Autosomal dominant defect in <i>NLRP3</i> , affecting cryopyrin
Neonatal-onset multisystem inflammatory disease (NOMID)	Chronic	Neonatal onset, hepatosplenomegaly, arthropathy, generalized urticarial-like rash, uveitis, chronic aseptic meningitis, sensorineural hearing loss	Anakinra	Autosomal dominant, often sporadic defect in <i>NLRP3</i> , affecting cryopyrin

TNF indicates tumor necrosis factor.

^a Reported therapy needing further investigation.

recurrent fever disorders exist together within a family of autoinflammatory diseases.

Interpretation of the data presented here must be viewed in light of several limitations. It is clearly impossible to diagnose a syndrome exemplified by recurrence after only a single episode. The patients described here initially presented with a classic constellation of symptoms consistent with a diagnosis of KS, were appropriately treated, and subsequently presented with a recurrent fever syndrome. However, the rarity of both KS and recurrent fever syndromes as individual disorders and the need for pattern recognition of symptoms to formulate the diagnosis are the limiting factors for larger studies. Given the delay in diagnosis frequently seen with recurrent fever syndromes because of the time required to establish recurrence, it is possible that additional patients with a

history of both KS and recurrent fever syndromes will be identified. However, to our knowledge, this association has not been previously described in the literature.

For the primary care physician, identification of these 2 relatively rare conditions creates a clinical challenge. However, historical features and subtle clinical findings may aid the clinician in reaching a diagnosis. Table 3 summarizes the clinical features of KS and hereditary and nonhereditary recurrent fever syndromes. Although mucosal involvement may be observed in both diseases, specific clinical manifestations for each disorder differ. KS is characterized by an injected oropharynx and conjunctiva, and patients with KS do not exhibit the aphthous stomatitis seen in some recurrent fever syndromes. Similarly, the strawberry tongue observed in patients with KS is absent in patients with recurrent fe-

ver. These mutually exclusive findings should be noted during a febrile episode and may lead the clinician toward a specific diagnosis. From a laboratory perspective, both KS and recurrent fever syndromes demonstrate elevated C-reactive protein level and erythrocyte sedimentation rate during the acute period, and they normalize between febrile episodes. The identification of a pattern of recurrent fevers with additional clinical signs (Table 3) becomes the most important diagnostic feature.

CONCLUSIONS

In this report we have described a subset of patients with KS who went on to develop recurrent fever syndromes, which indicates that these disorders may have a common immunologic thread, specifically related to immunodysregulation of innate immune effector mechanisms. For community pedi-

atricians treating patients with a history of KS, the recurrence of febrile episodes should lead to the consideration of alternative diagnoses, including recurrent fever syndromes.

REFERENCES

- Newburger JW, Takahashi M, Gerber MA, et al; Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease; Council on Cardiovascular Disease in the Young; American Heart Association; American Academy of Pediatrics. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. *Circulation*. 2004;110(17):2747–2771
- Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. *N Engl J Med*. 1991;324(23):1633–1639
- Wilder MS, Palinkas LA, Kao AS, Bastian JF, Turner CL, Burns JC. Delayed diagnosis by physicians contributes to the development of coronary artery aneurysms in children with Kawasaki syndrome. *Pediatr Infect Dis J*. 2007;26(3):256–260
- Tremoulet AH, Best BM, Song S, et al. Resistance to intravenous immunoglobulin in children with Kawasaki disease. *J Pediatr*. 2008;153(1):117–121
- Scully C, Hodgson T, Lachmann H. Auto-inflammatory syndromes and oral health. *Oral Dis*. 2008;14(8):690–699
- Yeung RSM. Kawasaki disease: update on pathogenesis. *Curr Opin Rheumatol*. 2010;22(5):551–560
- Hsieh YC, Wu MH, Wang JK, Lee PI, Lee CY, Huang LM. Clinical features of atypical Kawasaki disease. *J Microbiol Immunol Infect*. 2002;35(1):57–60
- Hirata S, Nakamura Y, Yanagawa H. Incidence rate of recurrent Kawasaki disease and related risk factors: from the results of nationwide surveys of Kawasaki disease in Japan. *Acta Paediatr*. 2001;90(1):40–44
- Levy M, Koren G. Atypical Kawasaki disease: analysis of clinical presentation and diagnostic clues. *Pediatr Infect Dis J*. 1990;9(2):122–126
- Rowley AH. Incomplete (atypical) Kawasaki disease. *Pediatr Infect Dis J*. 2002;21(6):563–565
- Hoffman HM, Simon A. Recurrent febrile syndromes: what a rheumatologist needs to know. *Nat Rev Rheumatol*. 2009;5(5):249–256
- Kao AS, Getis A, Brodine S, Burns JC. Spatial and temporal clustering of Kawasaki syndrome cases. *Pediatr Infect Dis J*. 2008;27(11):981–985
- Brosius CL, Newburger JW, Burns JC, Hojnowski-Diaz P, Zierler S, Leung DY. Increased prevalence of atopic dermatitis in Kawasaki disease. *Pediatr Infect Dis J*. 1988;7(12):863–866
- Matsuoka S, Tatara K, Nakagawa R, Mori K, Kuroda Y. Tendency toward atopy in Kawasaki disease. *Eur J Pediatr*. 1997;156(1):30–32
- Eberhard BA, Sundel RP, Newburger JW, et al. Psoriatic eruption in Kawasaki disease. *J Pediatr*. 2000;137(4):578–580
- Aukrust P, Müller F, Svenson M, Nordøy I, Bendtzen K, Frøland SS. Administration of intravenous immunoglobulin (IVIg) in vivo: down-regulatory effects on the IL-1 system. *Clin Exp Immunol*. 1999;115(1):136–143
- Bhol KC, Desai A, Kumari S, Colon JE, Ahmed AR. Pemphigus vulgaris: the role of IL-1 and IL-1 receptor antagonist in pathogenesis and effects of intravenous immunoglobulin on their production. *Clin Immunol*. 2001;100(2):172–180
- Hoffman HM. Therapy of autoinflammatory syndromes. *J Allergy Clin Immunol*. 2009;124(6):1129–1138
- Hoffman HM, Rosengren S, Boyle DL, et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. *Lancet*. 2004;364(9447):1779–1785
- Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. *Annu Rev Immunol*. 2009;27:621–668
- Burns JC, Glode MP. Kawasaki syndrome. *Lancet*. 2004;364(9433):533–544

from the American Academy of Pediatrics (awarded to Dr Broderick) and National Institutes of Health, National Heart, Lung, and Blood Institute grant K24 HL074864 (awarded to Dr Burns).